home / stock / okyo / okyo news

OKYO News and Press, OKYO Pharma Limited From 04/25/23

Stock Information
Company Name: OKYO Pharma Limited
Stock Symbol: OKYO
Market: NASDAQ
Website: okyopharma.com
Menu
OKYO OKYO Quote OKYO Short OKYO News OKYO Articles OKYO Message Board
Get OKYO Alerts

News, Short Squeeze, Breakout and More Instantly...
OKYO - OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease

LONDON and NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in this multi-billion...
OKYO - OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay

LONDON, UK and NEW YORK, NY / ACCESSWIRE / April 18, 2023 / Drug development can be notoriously slow, and it can take some companies 10 years or more to pass through all the trials and tests required by the Food and Drug Administration (FDA). However, when a company is bringing a drug to tri...

OKYO - Notice of General Meeting and Publication of Circular

LONDON and NEW YORK, April 05, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) (" OKYO " or the " Company "), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in this multi-...

OKYO - OKYO Pharma to delist from London Stock Exchange

2023-04-04 04:38:40 ET Ophthalmology-focused bio-pharmaceutical company, OKYO Pharma ( NASDAQ: OKYO ) i ntends to delist from LSE or London Stock Exchange. The delisting will have no impact on the company’s ADSs which are traded on Nasdaq. The reason for delisti...
OKYO - Notice of Intention to Delist From The London Stock Exchange

LONDON and NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) (" OKYO " or the " Company "), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in this multi-...

OKYO - OKYO Pharma Today Announces Director Acquires Shares

LONDON and NEW YORK, March 29, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) (“OKYO” or the “Company“), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED“) to address the...

OKYO - OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4

(NewsDirect) By David Willey, Benzinga Drug development isn’t known for being fast-paced, and developing any new drug is generally a long process. However, OKYO Pharma Ltd. (NASDAQ: OKYO) is moving quickly to develop its eye treatment drug, OK-101. It plans to begin trials for ...
OKYO - Okyo's executive chairman linked entity buys 10K ADSs

2023-03-24 06:35:35 ET Okyo Pharma ( NASDAQ: OKYO ) said Panetta Partners, an entity in which the company's Executive Chairman Gabriele Cerrone has a beneficial interest, bought 10K ADSs at US$1.40 per ADS (American depositary shares). The ADSs would be equivalent to ...

OKYO - OKYO Pharma Announces PDMR Dealing

LONDON and NEW YORK, March 24, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) (“OKYO” or the “Company“), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED“) to address the...

OKYO - Why Is Okyo Pharma (OKYO) Stock Up 13% Today?

2023-03-16 10:19:06 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Okyo Pharma (NASDAQ: OKYO ) stock is on the rise Thursday as investors react to news about its Phase 2 clinical trial of OK-101 . OK-101 is the company’s drug can...
Previous 10 Next 10